Biotechnology News and Research

RSS

FDA provides Orphan Drug Designation to Alnylam’s ALN-TTR02

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the U.S. Food & Drug Administration (FDA) has provided Orphan Drug Designation to ALN-TTR02 as a therapeutic for the treatment of familial amyloidotic polyneuropathy (FAP), one of the predominant clinical manifestations of transthyretin (TTR)-mediated amyloidosis (ATTR).

20 Jun 2012

Furiex initiates MuDelta Phase III studies in IBS-D

Furiex Pharmaceuticals, Inc. today announced dosing of the first patient in its Phase III randomized, double-blind, placebo-controlled studies evaluating efficacy, safety and tolerability of MuDelta (JNJ-27018966) in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).

20 Jun 2012

SDIX advanced Genomic Antibody Technology to be highlighted at BIO International Convention

SDIX today announced that it will be showcasing progress with its advanced Genomic Antibody Technology data package this week's BIO International Convention, one of the largest global partnering events for the biotechnology industry.

19 Jun 2012

SickKids, Life Technologies partner to advance pediatric genomic research on Ion Proton Sequencer

Life Technologies Corporation today announced it has partnered with The Hospital for Sick Children (SickKids) to advance pediatric genomic research on the Ion Proton Sequencer.

19 Jun 2012

e-Therapeutics commences enrollment in ETS2101 phase I trial for brain cancer

e-Therapeutics plc announces the start of the first clinical trial evaluating its compound ETS2101 as a treatment for cancer. The phase I trial is enrolling patients with primary brain cancer (glioma) or cancer that has spread to the brain from other sites.

19 Jun 2012

Comprehensive data analysis and interpretation offered to customers as a result of collaboration between ATLAS Biolabs and Ingenuity systems

ATLAS Biolabs and Ingenuity® Systems have signed a collaboration agreement that gives ATLAS Biolabs’ customers the option to analyse and interpret their study data using Ingenuity solutions.

19 Jun 2012

Next-generation sequencing technologies for the 1,000 Rare Diseases Project

BGI, the world's largest genomics organization, and The Children's Hospital of Philadelphia (CHOP) today announced that they have jointly initiated the 1,000 Rare Diseases Project with the aim of accelerating the discovery of genetic variants underlying rare diseases.

19 Jun 2012

Single-dose vaccine for treatment of cocaine addiction

A single-dose vaccine capable of providing immunity against the effects of cocaine offers a novel and groundbreaking strategy for treating cocaine addiction is described in an article published Instant Online in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc.

19 Jun 2012

Life Technologies introduces three next generation genetic engineering kits

Life Technologies Corporation today announced the launch of three next generation GeneArt genetic engineering kits that allow molecular and synthetic biologists unprecedented speed, flexibility, precision, and efficiency for the seamless cloning, assembly, and editing of genetic material.

19 Jun 2012

New clinical data for ZEVALIN Injection for intravenous use presented at 17th EHA Congress

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology and hematology, today announced new clinical data presented in an oral presentation for ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use at the 17th Congress of the European Hematology Association (EHA).

19 Jun 2012

T2Endotoxin assay extends reach of T2MR detection

T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the presentation of data on endotoxin detection at the American Society for Microbiology General Meeting, June 16-19, 2012, in San Francisco, CA.

18 Jun 2012

Positive interim data from Innate MIS416 Phase 1/2 clinical trial for chronic progressive MS

Innate Immunotherapeutics today announced positive interim data from the company's Phase 1/2 clinical trial of MIS416 in patients with chronic progressive multiple sclerosis (MS).

18 Jun 2012

KineMed, GSK enter multi-year biomarker discovery partnership

KineMed, Inc. announced today a multi-year R&D collaboration with GlaxoSmithKline plc that will apply KineMed's proprietary biomarker discovery platform in therapeutic areas of interest to GSK.

18 Jun 2012

Zealand Pharma, Protagonist partner to develop novel disulfide-rich peptides

Zealand Pharma A/S, a Danish biotechnology company dedicated to the discovery and development of novel peptide drugs, has signed a collaboration agreement with Protagonist Therapeutics, Inc., a privately-owned US incorporated biotechnology company.

18 Jun 2012

PAREXEL launches fully-integrated eClinical solution

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced the launch of the PAREXEL MyTrials platform, a fully-integrated eClinical solution that simplifies the clinical trial process.

From Parexel 18 Jun 2012

Wellcome Trust awards University of Maryland $4M to accelerate development of conjugate NTS vaccine

The University of Maryland School of Medicine's Center for Vaccine Development (CVD) has received a $4 million Strategic Translation Award from the prestigious Wellcome Trust to support a collaboration with Bharat Biotech for clinical development of a new conjugate vaccine to prevent the potentially lethal infectious disease caused by invasive non-typhoidal Salmonella.

18 Jun 2012

iPS Academia Japan, Life Technologies partner for induced pluripotent stem cell patent portfolio

Life Technologies Corporation today announced that it has deepened its commitment to stem cell research and its customers by signing a non-exclusive agreement with iPS Academia Japan for its induced pluripotent stem (iPS) cell patent portfolio.

16 Jun 2012

People can train their brains to become less impulsive

New research from psychologists at the Universities of Exeter and Cardiff shows that people can train their brains to become less impulsive, resulting in less risk-taking during gambling. The research could pave the way for new treatments for people with addictions to gambling, drugs or alcohol as well as impulse-control disorders, such as ADHD.

15 Jun 2012

ISCO develops new TTF-based stem cell technology

International Stem Cell Corporation announced that scientists in its wholly-owned subsidiary, Lifeline Cell Technology (LCT), have developed a technology to modify human stem cells by using engineered proteins, called "transducible transcription factors" or "TTFs."

15 Jun 2012

Positive top-line results from Teva’s GALA Phase III trial on RRMS

Teva Pharmaceutical Industries Ltd. today announced positive top-line results from the GALA (Glatiramer Acetate Low-Frequency Administration) Phase III clinical trial assessing the efficacy, safety and tolerability of 40 mg/1 ml glatiramer acetate injection (GA) administered subcutaneously three times a week compared to placebo in relapsing-remitting multiple sclerosis (RRMS) patients.

15 Jun 2012